Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season
JAMA Network Open · 17.06.2026 · 9 (6) · e2618581
DOI: 10.1001/jamanetworkopen.2026.18581 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 17.06.2026. Verfasst von Eduardo Azziz-Baumgartner und 42 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: Influenza, Human, Vaccine Efficacy, Influenza Vaccines, Influenza A Virus, H3N2 Subtype. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Antigenically drifted influenza A(H3N2) J.2.4.1 (subclade K) viruses predominated during the 2025-2026 Northern Hemisphere influenza season.
Objective
To describe influenza activity and burden, characterize subclade K, evaluate susceptibility to influenza antivirals and postinfluenza vaccination antibodies, and estimate vaccine effectiveness. Design, Setting, and Participants This surveillance study used multiple data sources, including (1) national surveillance of influenza-positive respiratory specimens collected by approximately 300 clinical laboratories and 100 public health laboratories from October 1, 2025, through March 14, 2026, a subset of which were further characterized; (2) serologic data of people who received 2025-2026 influenza vaccines; (3) influenza admissions data from the Influenza Hospitalization Surveillance Network (ie, 10% of US population) and the associated estimates of US burden; and (4) test-negative, case-control vaccine effectiveness estimates from the Virtual SARS-CoV-2, Influenza, and Other Respiratory Viruses Network. Exposures Influenza infection, hospitalization, and vaccination. Main Outcomes and Measures Outcomes included influenza virus type, subtype, and clade; antiviral susceptibility; immunogenicity; influenza-associated outpatient and emergency department visits, hospitalizations, and mortality; estimated influenza illnesses, hospitalizations, and death; and estimated vaccine effectiveness.
Results
As of March 14, 2026, of the 55 318 influenza-positive respiratory specimens tested by public health laboratories, most (50 291 specimens [90.9%]) were influenza A, of which 40 779 (81.1%) were subtyped and 35 801 (87.8%) were A(H3N2). Of the 1754 characterized A(H3N2) viruses, most (1626 specimens [92.7%]) were subclade K. Postinfluenza vaccination neutralizing geometric mean antibody titers against subclade K were reduced 1.62 (95% CI, 1.29-2.02)–fold compared with the vaccine virus. All 1729 tested A(H3N2) viruses were sensitive to antivirals. Of the 27 881 recorded influenza hospitalizations, 15 426 (54.7%) were among female patients, and 15 051 (54.0%) were among patients aged 65 years or older. The estimated cumulative influenza-associated hospitalization rate was 80.0 per 100 000 which would correlate with estimates of between 28 000 000 to 49 000 000 illnesses, 360 000 to 740 000 hospitalizations, and 22 000 to 74 000 deaths in the US during the 2025-2026 season. Adjusted interim vaccine effectiveness estimates against influenza-associated emergency department or urgent care encounters and hospitalizations were 35% (95% CI, 33%-38%) and 27% (95% CI, 21%-34%), respectively. Conclusions and Relevance This surveillance study found that while antigenically drifted viruses predominated and caused substantial morbidity and mortality, influenza vaccines were associated with a reduced risk of influenza among those who were vaccinated, and recommended antivirals remained effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Kaiser Permanente Center for Health Research, Portland, Oregon.
- Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah.
- Immunization Programs, Intermountain Health, Salt Lake City, Utah.
- HealthPartners Institute, Minneapolis, Minnesota.
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.
Zitieren
APA
Azziz-Baumgartner, E., Budd, A., Lee, J. S., Iuliano, A. D., Ellington, S. R., Levine, M. Z., Zheng, X. Y., Gubareva, L., Adams, K., DeCuir, J., Bozio, C. H., Reed, C., Kirby, M. K., Rambo-Martin, B., Jones, J. M., Biggerstaff, M., Garg, S., Davis, C. T., Shimabukuro, T. T., …, & Ray, C. S. (2026). Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Network Open, 9(6), e2618581. https://doi.org/10.1001/jamanetworkopen.2026.18581
Vancouver
Azziz-Baumgartner E, Budd A, Lee JS, Iuliano AD, Ellington SR, Levine MZ, et al. Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Network Open. 2026;9(6):e2618581. doi:10.1001/jamanetworkopen.2026.18581
BibTeX
@article{AzzizBaumgartner2026,
author = {Azziz-Baumgartner, Eduardo and Budd, Alicia and Lee, Justin S and Iuliano, A Danielle and Ellington, Sascha R and Levine, Min Z and Zheng, Xiao-Yu and Gubareva, Larisa and Adams, Katherine and DeCuir, Jennifer and Bozio, Catherine H and Reed, Carrie and Kirby, Marie K and Rambo-Martin, Benjamin and Jones, Jefferson M and Biggerstaff, Matthew and Garg, Shikha and Davis, Charles Todd and Shimabukuro, Tom T and Burns, Erin and Kondor, Rebecca and Olsen, Sonja J and Dugan, Vivien G and VISION Coauthors, VISION Coauthors and Irving, Stephanie A and Naleway, Allison L and Dascomb, Kristin and Sheffield, Tamara and DeSilva, Malini B and Tartof, Sara Y and Sy, Lina S and Klein, Nicola P and Zerbo, Ousseny and Grannis, Shaun J and Dixon, Brian E and Stockwell, Melissa S and Stephens, Ashley B and Ong, Toan C and Barron, Michelle A and Ball, Sarah W and Weber, Zachary A and Reeves, Emily L and Ray, Caitlin S},
title = {Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {6},
pages = {e2618581},
doi = {10.1001/jamanetworkopen.2026.18581}
}
EUVIMED